Samsara Bio Capital, LLC Arcellx, Inc. Transaction History
Samsara Bio Capital, LLC
- $217 Million
- Q1 2025
A detailed history of Samsara Bio Capital, LLC transactions in Arcellx, Inc. stock. As of the latest transaction made, Samsara Bio Capital, LLC holds 135,276 shares of ACLX stock, worth $9.54 Million. This represents 4.1% of its overall portfolio holdings.
Number of Shares
135,276
Previous 253,641
46.67%
Holding current value
$9.54 Million
Previous $19.3 Million
54.06%
% of portfolio
4.1%
Previous 5.92%
Shares
10 transactions
Others Institutions Holding ACLX
# of Institutions
211Shares Held
48.5MCall Options Held
764KPut Options Held
296K-
Paradigm Biocapital Advisors LP New York, NY4.49MShares$317 Million15.1% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.99MShares$281 Million0.0% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$264 Million23.3% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$248 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA3.04MShares$214 Million4.14% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $3.09B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...